Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 35Carcinoma, Hepatocellular 28Stomach Neoplasms 12Neoplasm Metastasis 12Nasopharyngeal Carcinoma 11Neoplasms 10Esophageal Neoplasms 10Melanoma 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 8Recurrence 7Lung Neoplasms 7Breast Neoplasms 7Biliary Tract Neoplasms 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 5Rectal Neoplasms 5Pancreatic Neoplasms 5Head and Neck Neoplasms 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Sarcoma 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Hyperthermia 3

Interventions

Immune Checkpoint Inhibitors 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immune-related Adverse Event × Immune Checkpoint Inhibitors × Clear all
NCT06702566 2024-11-25

The Effect of Serum Ferritin in irAE

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
1,500 enrolled
Other hematologic neoplasmOther solid neoplasm

Immune-related Adverse Event

Data powered by HemOnc (CC BY 4.0) Colophon âš¡